Drugs and vaccines for COVID-19: List of authorized clinical trials
On this page
The tables below list the COVID-19-related clinical trials that have been authorized by Health Canada. These trials have been authorized through either:
- the Food and Drug Regulations or
- Interim Order No. 2, which was replaced by the Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations on February 27, 2022
This listing represents the initial authorization of the trial, but does not necessarily indicate that the trial is currently active. Status of the trial should be confirmed with the authorization holder.
Health Canada continues to discuss potential clinical trials with a number of sponsors. We will update the lists as new trials related to drugs or vaccines for COVID-19 are authorized.
List of COVID-19 vaccine trials
| Trial name /Protocol #/control # | Title | Interventions | Authorization holder | Authorization date | Clinicaltrials.gov link |
|---|---|---|---|---|---|
| VBI-2901E (Control # 268572) Authorized under the Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations |
A Phase 1, Open-Label, Adjuvant Dose-Escalation, Randomized Study To Evaluate The Safety And Immunogenicity Of Vbi-2901e, A Trivalent Coronavirus Vaccine Candidate Adjuvanted With Aluminum Phosphate And E6020 In Healthy Adults Previously Vaccinated With Licensed Covid-19 Vaccines | Vaccine: VBI-2901E |
Variation Biotechnologies Inc. | 2022-10-25 | N/A |
| COVAC-1 (Control # 267708) Authorized under the Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations |
A Randomized, Observer-Blind, Dose Escalation, Placebo-Controlled, Phase 1 Clinical Trial To Study The Safety And Immunogenicity Of A Covac-1 Booster Dose In Generally Healthy Adults | Vaccine: COVAC-1 (nCOV19 S1) |
University of Saskatchewan | 2022-09-28 | N/A |
| VBI-2901A (Control # 267517) Authorized under the Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations |
A Phase 1, Randomized Study To Evaluate The Safety And Immunogenicity Of VBI- 2901a, A Trivalent Coronavirus Vaccine Candidate In Healthy Adults Previously Vaccinated With Licensed Covid-19 Vaccines | Vaccine: VBI-2901A |
Variation Biotechnologies Inc. | 2022-09-15 | N/A |
| COVB-2022-1 (Control # 261144) Authorized under the Clinical Trials Interim Order | Covid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases (COVBIRD) | SPIKEVAX (Elasomeran (mRNA)) / NUVAXOVID (COVID-19 Vaccine (Recombinant protein, Adjuvanted)) | CHU de Québec – Université Laval | 2022-02-18 | NCT05236491 |
| CP-PRO-CoVLP-026 (Control # 259935) Authorized under the Clinical Trials Interim Order |
A Randomized, Partially-Blind, Multicenter, Phase 3 Study to Assess the Safety, Tolerability, and Immunogenicity of a Booster Dose of a Homologous or Heterologous Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults Previously Vaccinated with a COVID-19 Vaccine | Vaccines: Coronavirus-like Particle (CoVLP) COVID-19 Vaccine / CoVLP.B1351 COVID-19 Vaccine |
Medicago Inc. | 2022-01-19 | N/A |
| COVAC-004 (Control # 259104) Authorized under the Clinical Trials Interim Order |
A Phase 1/2 Clinical Trial to Study Safety, Tolerability, and Immunogenicity of a COVAC-2 Booster Dose in Generally Healthy Adults | Vaccine: COVAC-2 (nCoV19 S1) | University of Saskatchewan, VIDO | 2021-12-23 | NCT05226702 |
| MP-37-2021-7562 (Control # 258049) Authorized under the Clinical Trials Interim Order |
COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases | Vaccines: SPIKEVAX (Elasomeran (mRNA)) |
Research Institute of the McGill University Health Centre | 2021-11-08 | NCT04806113 |
M010 |
Phase 1, Open Label Study to Evaluate the Safety and Immunogenicity of ChAd68 and AdHu5 vector-based Trivalent COVID-19 Vaccines Delivered Via Inhaled Aerosol | ChAd-CoV/Mac / Ad5-CoV/Mac | McMaster University | 2021-10-21 | NCT05094609 |
PRO-CL-002 (Control # 253878) Authorized under the Clinical Trials Interim Order |
A Phase 2, Randomized, Observer-Blind, Study to Evaluate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Compared to Pfizer-BioNTech COVID-19 Vaccine in Healthy Seronegative Adults Aged 18 to 64 Years | PTX-COVID19-B / Pfizer-BioNTech COVID-19 Vaccine | Providence Therapeutics Holdings, Inc. | 2021-07-20 | N/A |
| 3750 (Control # 255889) Authorized under the Clinical Trials Interim Order |
BOOST KIDNEY: A Multi-Centre 12 Month Parallel-Group Randomized Control Trial of BNT162b2 versus mRNA-1273 COVID-19 Vaccine Boosters in Chronic Kidney Disease and Dialysis Patients With Poor Humoral Response following COVID-19 Vaccination | COMIRNATY Vaccine (BNT162b2 mRNA Covid-19 Vaccine) / SPIKEVAX Vaccine (mRNA-1273 SARS-CoV-2 Vaccine) | Sunnybrook Research Institute | 2021-09-02 | NCT05022329 |
| Moderna RCT LTCF (Control # 255430) Authorized under the Clinical Trials Interim Order |
Third Dose of Moderna mRNA-1273 COVID-19 Vaccine in Residents of Long-Term Care Facilities | Moderna COVID-19 vaccine (mRNA-1273 vaccine) | McMaster University | 2021-08-13 | NCT04978038 |
| mRNA-1273-P204 (Control #254169) Authorized under the Clinical Trials Interim Order |
A Phase 2/3, Two-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Children 6 Months to Less Than 12 Years of Age | COVID-19 Vaccine Moderna (mRNA-1273 SARS-CoV-2 vaccine) | ModernaTX, Inc | 2021-07-08 | NCT04796896 |
| ALT-501-102 (Control # 252058) Authorized under the Clinical Trials Interim Order |
A Phase 1, Open-label Study to Evaluate the Effect of Position and Duration on the Safety and Immunogenicity of Intranasal AdCOVID Administration | AdCOVID Vaccine | Altimmune, Inc. | 2021-05-26 | N/A |
CT24 |
Immunogenicity and adverse events following immunization (AEFI) with alternate schedules of COVID-19 vaccines in Canada: is “mix and match” of the second dose (MOSAIC-a;CT24a) and third dose (MOSAIC-2;CT24b) safe and immunogenic? | Vaccines: Comirnaty Pfizer-BioNTech COVID-19 Vaccine, mRNA) / SpikeVax (Moderna Elasomeran mRNA vaccine) | Dalhousie University/Canadian Immunization Research Network (CIRN) | 2021-05-05 | NCT04894435 |
KBP-201 |
A Phase I/II, First-in-human, Observer-blinded, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Immunogenicity of TAP-COVID-19 SARS-CoV-2 Vaccine with CpG Adjuvant in Healthy Adults Aged 18-49 and 50-85
|
TAP-COVID-19 | Kentucky Bioprocessing, Inc. | 2021-05-03 | NCT04473690 |
| UHN-TID-COVAX-2 (Control # 251583) |
A randomised, single blind, controlled trial of a third dose of Moderna vaccine versus placebo in solid organ transplant recipients | Moderna COVID-19 vaccine (mRNA-1273 SARS-CoV-2 vaccine) | University Health Network | 2021-04-26 | NCT04885907 |
| VAC31518COV2004 (Control # 250107) Authorized under the Clinical Trials Interim Order |
An Open-label, Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.COV2.S in Healthy Pregnant Participants | Jcovden (Ad26.COV2.S (JNJ-78436735)) | Janssen Inc. | 2021-03-17 | NCT04765384 |
| Ad5-nCoV-2020003 (Control # 239283) |
A Randomized, Observer-Blind, Dose-escalation Phase I/II Clinical Trial of Ad5-nCoV Vaccine in Healthy Adults from 18 to <85 years of age in Canada | Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5) (Ad5-nCoV) | CanSino Biologics Inc. | 2020-05-15 | NCT04398147 |
| COBRA (Control # 238868) |
A Randomized, Double-blind, Placebo-Controlled Phase 3 Study: Efficacy and Safety of Recombinant BCG VPM1002 in Reducing SARS-CoV-2 Infection Rate and COVID-19 Severity | Recombinant Mycobacterium bovis BCGΔureC::hly |
Princess Margaret Cancer Centre | 2020-05-08 | NCT04439045 |
| COVAC-001 (Control # 247198) Authorized under the Clinical Trials Interim Order |
A Randomized, Observer-Blind, Dose-Escalation Phase I Clinical Trial of COVAC-2 in Healthy Adults | COVAC-2 (nCoV19 S1) | University of Saskatchewan, VIDO | 2020-12-22 | NCT04702178 |
| CP-PRO-CoVLP-019 (Control # 240922) |
A Randomized, Partially-Blinded, dose-Ranging Phase 1 Study to Assess the Safety, Tolerability, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18-55 Years of Age | Coronavirus-like Particle (CoVLP) COVID-19 Vaccine | Medicago Inc. | 2020-07-09 | NCT04450004 |
| CP-PRO-CoVLP-021 (Control # 245149) Authorized under the Clinical Trials Interim Order |
A Randomized, Observer-Blind, Placebo-Controlled Phase 2/3 Study to Assess the Safety, Efficacy, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18 Years of Age or Older | Coronavirus-like Particle (CoVLP) COVID-19 Vaccine | Medicago Inc. | 2020-11-09 | NCT04636697 |
| IC.8 (Control # 240586) Authorized under the Clinical Trials Interim Order |
COV-IMMUNO - A Randomized, Phase III Trial of Immunization with IMM-101 versus Observation for the Prevention of Severe Respiratory and COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure | IMM-101 | Canadian Cancer Trials Group, Cancer Research Institute, Queen's University | 2020-06-24 | NCT04442048 |
| PRO-CL-001 (Control # 246974) Authorized under the Clinical Trials Interim Order |
A Phase I, First-in-Human, Observer-Blinded, Randomized, Placebo Controlled, Ascending Dose Study to Evaluate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64 | PTX-COVID19-B | Providence Therapeutics Holdings Inc. | 2020-12-22 | NCT04765436 |
| VAC31518COV2001 (Control # 246908) Authorized under the Clinical Trials Interim Order |
A Randomized, Double-blind, Placebo-Controlled Phase 2a Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and Older and to Evaluate 2 Dose Levels of Ad26.COV2.S in Healthy Adolescents Aged 12 to 17 Years Inclusive | Jcovden (Ad26.COV2.S (JNJ-78436735)) | Janssen Inc. | 2020-12-14 | NCT04535453 |
| VBI-2902a-CT01 (Control # 246985) Authorized under the Clinical Trials Interim Order |
A Phase 1a/1b, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the COVID-19 (SARS-CoV-2) Vaccine Candidates VBI-2902a and VBI-2905a in Healthy Adults | VBI-2902a / VBI-2905a | VBI Vaccines Inc. | 2020-12-18 | NCT04773665 |
| ENTVAX01-101 (Control # 250321) Authorized under the Clinical Trials Interim Order |
Phase I/II Study to Evaluate Safety, Tolerability, Immunogenicity of a Prophylactic Plasmid DNA Vaccine against SARS CoV-2 (Covigenix VAX-001) in Healthy Adults 18 Years and Older | Covigenix VAX-001 | Entos Pharmaceuticals Inc. | 2021-03-24 | NCT04591184 |
List of COVID-19 treatment trials
| Trial name /Protocol #/control # | Title | Interventions | Authorization holder | Authorization date | Clinicaltrials.gov link |
|---|---|---|---|---|---|
U1111-1311-3673 / control# 288823 Authorized under the COVID-19 Regulations |
Antiviral Strategies in the Prevention of Long-Term Cardiovascular Outcomes Following COVID-19: The Paxlovid /Remdesivir Effectiveness for the Prevention of Long COVID (DEFEND) CLINICAL TRIAL | Nirmatrelvir / Ritonavir / Remdesivir | Sinai Health System | 2024.08.23 | N/A |
| LAU-23-01 / control# 277639 | A Double-Blind, Randomized, Placebo-Controlled, Adaptive, Phase 2/3 Study of the Efficacy of LAU-7B in the Treatment of Adults with Long COVID and Moderate to Severe Symptoms | Fenretinide (LAU-7B) | Laurent Pharmaceuticals | 2023-08-22 | N/A |
| GS-US-611-6549 / control# 277480 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5245 For the Treatment of F COVID-19 in Non-Hospitalized Participants | Obeldesivir (GS-5245) | Gilead Sciences Canada Inc. | 2023-08-22 | N/A |
| C4671028 / control# 271389 | A Phase 1, Open-Label Randomized Study to Investigate the Safety and PK Following Multiple Oral Doses of PF-07321332 (Nirmatrelvir)/Ritonavir in Adult Participants with COVID-19 and Severe Renal Impairment either on Hemodialysis or Not on Hemodialysis | PF-07321332 (Nirmatrelvir)/Ritonavir | Pfizer Canada ULC | 2023-03-29 | N/A |
| OZUHN-004 / control# 271810 | Platform Of Randomized Adaptive Clinical Trial in Critical Illness (PRACTICAL) Randomized Control Trial | Dexamethasone | University Health Network | 2023-02-07 | N/A |
|
OZUHN-002 / control # 271420 Authorized under the COVID-19 Regulations |
Recovering From COVID19 Lingering Symptoms Adaptive Integrative Medicine (RECLAIM) | Pentoxifylline / Ibudilast (MN-166) | University Health Network | 2023-01-25 and 2023-02-03 | NCT05513560 |
AT-03A-017 / control # 269964 Authorized under the COVID-19 Regulations |
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BEMNIFOSBUVIR IN HIGH-RISK OUTPATIENTS WITH COVID-19 | BEMNIFOSBUVIR (BEM; AT-527) | ATEA PHARMACEUTICALS INC. | 2022-12-06 | NCT05614349 |
CANTREATCOVID-1 / control # 269011 Authorized under the COVID-19 Regulations |
CANADIAN ADAPTIVE PLATFORM TRIAL OF TREATMENTS FOR COVID IN COMMUNITY SETTINGS (CANTREATCOVID) | NIRMATRELVIR / RITONAVIR | UNITY HEALTH TORONTO | 2022.11.02 | NCT05614349 |
| C4671042 / control # 268341 |
An interventional, efficacy and safety, phase 2, randomized, double-blind, 2-arm study to investigate a repeat 5-day course of nirmatrelvir/ritonavir compared to placebo/ritonavir in participants at least 12 years of age with rebound of COVID-19 symptoms and rapid antigen test positivity | Nirmatrelvir (PF-07321332)/ Ritonavir | Pfizer Canada ULC | 2022-10-28 | N/A |
| GS-US-611-6273 / control # 267297 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF GS-5245 FOR THE TREATMENT OF COVID-19 IN PARTICIPANTS WITH HIGH-RISK FOR DISEASE PROGRESSION | GS-5245 | Gilead Sciences Canada Inc. | 2022-09-20 | N/A |
| C4671034 / Control # 265231 | AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2, RANDOMIZED, DOUBLE-BLIND, 3 ARM STUDY TO INVESTIGATE NIRMATRELVIR/RITONAVIR IN NON-HOSPITALIZED PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH SYMPTOMATIC COVID 19 WHO ARE IMMUNOCOMPROMISED | NIRMATRELVIR (PF-07321332) / RITONAVIR | PFIZER CANADA ULC | 2022-08-02 | N/A |
| H21-02254 Control # 263975 | A DOUBLE BLIND RANDOMIZED TRIAL OF LOW-DOSE NALTREXONE FOR POST-COVID FATIGUE SYNDROME | Treatment: NALTREXONE | BRITISH COLUMBIA WOMENS HOSPITAL | 2022-06-01 | N/A |
| PTC299-VIR-015-COV19 (Control # 260607) |
Evaluation of the efficacy and safety of PTC299 in hospitalized subjects with covid-19 (FITE19) | EMVODODSTAT (PTC299) | PTC THERAPEUTICS INC | 2022-02-02 | N/A |
| BCDF002 (Control # 255061) |
Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Vortioxetine For Cognitive Deficits in Persons with Post-COVID-19 Syndrome | Vortioxetine | Brain and Cognition Discovery Foundation | 2021-08-17 | N/A |
| CARDIOL 100-03 (Control #254314) |
Study to Evaluate the Efficacy and Safety of CARDIOLRX in Patients with COVID-19 and Cardiovascular Disease or Risk Factors, a Double-Blind, Placebo-Controlled Trial (LANCER) | Cannabidiol (CARDIOLRX) | Cardiol Therapeutics Inc. | 2021-07-16 | NCT04615949 |
| SAMI-06-1-01 (Control # 253521) |
A Randomized, Placebo-Controlled Phase II Study to Evaluate the Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects with Persistent Respiratory Symptoms | S-1226 (Carbon Dioxide-Perflubon) | Solaromed Inc. | 2021-06-21 | NCT04949386 |
| COVID-NONS-05 (Control # 252713) |
Multi-Center, Double-Blinded, Placebo-Controlled Parallel, Phase 3 Clinical Efficacy Study Evaluating Nitric Oxide Nasal Spray (NONS) to Treat and Prevent the Exacerbation of Infection in Individuals with Documented Mild COVID-19 | Nitric oxide | Sanotize Research & Development Corp. | 2021-05-25 | N/A |
| 20210072-01H (Control # 251410) |
Dietary supplements to reduce symptoms severity and duration in people with SARS-COV-2: A randomized, double-blind, placebo controlled clinical trial | Vitamin D / Vitamin K-Vitamin D | Ottawa Hospital Research Institute | 2021-05-21 | NCT04780061 |
| WV43042 (Control # 252494) |
A phase II randomized, double-blind, placebo controlled study to evaluate the antiviral activity safety, pharmacokinetics, and efficacy of RO7496998 (AT-527) in non-hospitalized adult patients with mild or moderate COVID-19 | AT-527 (RO7496998) | Hoffman La Roche Limited | 2021-05-20 | NCT04709835 |
| EXTEND-P2 (Control # 246808) Authorized under the Clinical Trials Interim Order |
Extend (Novel oxygen therapeutic NANO2 for COVID-19) Phase IB/II trial | Perflenapent (NANO2) | Nuvox Pharna LLC | 2021-05-17 | N/A |
| COVID-NONS-04 (Control # 252244) |
Decentralized, randomized, double-blinded, placebo-controlled, phase 3 clinical efficacy study evaluating nitric oxide nasal spray (NONS) as prevention for treatment of individuals at risk of exposure to COVID-19 infection | Nitric oxide | Sanotize Research & Development Corp | 2021-05-14 | N/A |
| 1000074027 (Control # 251634) |
Lung Structure-Function in Survivors of Mild and Severe COVID19 Infection: 129XE MRI for Rapid Evaluation and Nextwave Healthcare Planning (LIVECOVIDFREE) | Hyperpolarized Xenon-129 | The Hospital for Sick Children | 2021-04-29 | N/A |
| CIRCA-19 RCT (Control # 250736) |
Cellular Immuno-Therapy for COVID-19 ARDS (CIRCA-19) Randomized Clinical Trial | Allogeneic Umbilical Cord Mesenchymal Stromal Cells (UC-MSCs) | Ottawa Hospital Research Institute | 2021-04-13 | NCT04400032 |
| ACTIV-2/A5401 (Control # 250685) Authorized under the Clinical Trials Interim Order |
Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID) | BRII-196 / BRII-198 / SAB-185/ BMS-986413/BMS-986414 / SNG001 (Interferon-β1a) / REGN10933 (Casirivimab)+REGN10987 (Imdevimab) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-04-08 | NCT04518410 |
| 216912 (Control # 250948) Authorized under the Clinical Trials Interim Order |
A Multicenter, Randomized, Double-Blind, Parallel Group Phase II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Second Generation VIR-7831 Material in Non-Hospitalized Participants with Mild to Moderate Coronavirus Disease 2019 (COVID-19) | VIR-7831 (GSK4182136) | Vir Biotechnology Inc. | 2021-04-09 | NCT04779879 |
| RVX222-CS-023 (Control # 250480) |
An Open-Label Study to Assess the Safety and Effect on Clinical Course and Key Biomarkers of Oral Apabetalone in Hospitalized Subjects with COVID-19 Infection in Addition to Standard of Care (SOC) | RVX000222 (Apabetalone) | Resverlogix Corp | 2021-04-06 | N/A |
| CORE-COVID (Control # 249936) |
A Randomized Clinical Trial Comparing 7 Days Treatment with Corticosteroids Versus Placebo for Early COVID-19 | Prednisone | Governors of The University of Alberta | 2021-03-08 | N/A |
| CPI-006-003 (Control # 249442) Authorized under the Clinical Trials Interim Order |
Phase 3, Randomized, Placebo Controlled, Double-blind, Multicenter, Stratified Study of CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized COVID-19 Patients | CPI-006 | Corvus Pharmaceuticals, Inc. | 2021-03-01 | NCT04734873 |
| COVID-NORS-01 (Control # 247971) |
The Efficacy of Topical Nitric Oxide Releasing Solutions (NORS) in the Management of Coronavirus Disease 2019 (COVID-19) | Nitric Oxide | St. Paul's Hospital Vancouver | 2021-01-15 | N/A |
| JF-12-2020 (Control # 247938) |
TOGETHER-Toronto: A phase III randomized, double-blind, placebo-controlled, multicenter, trial to evaluate the effect of peginterferon lambda for the treatment of COVID-19 | Peginterferon Lambda-1A | University Health Network | 2021-01-13 | N/A |
| SAMI-05-1-01 (Control # 247617) |
A Randomized, Open-Label, Controlled, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of S-1226 in Hospitalized Subjects with Moderate Severity COVID-19 | S-1226 (Carbon-Dioxide Perflubron) | Solaeromed Inc. | 2020-12-31 | N/A |
| REDA-10122 (Control #248696) Authorized under the Clinical Trials Interim Order |
Annexin A5 in Patients with Severe COVID-19 Disease | SY-005 (Recombinant Human Annexin A5) | Lawson Health Research Institute | 2021-02-05 | NCT04748757 |
| 115769 (Control # 238857) |
Safety and Efficacy of Post-Exposure Prophylaxis with Hydroxychloroquine (HCQ) for the prevention of Corona Virus Infectious Disease-19 (COVID-19) in high-risk patients/residents in Institutions | Hydroxychloroquine | St. Joseph's Health Care Parkwood site | 2020-05-09 | NCT04371523 |
| 20-5449 (Control # 239579) |
Use of High Dose Inhaled Nitric Oxide in Intubated Patients Admitted with COVID-19 | Nitric oxide | University Health Network | 2020-06-25 | NCT04383002 |
| 2021-6954 (Control # 244461) Authorized under the Clinical Trials Interim Order |
Treatment of Respiratory Complications Associated with COVID-19 Infection Using Wharton's Jelly (WJ)-Umbilical Cord (UC) Mesenchymal Stromal Cells (ProTrans): a Randomized Phase II Controlled Clinical Trial | ProTrans (Wharton's Jelly derived Umbilical Cord Mesenchymal Stromal Cells (UCMSC) | Research Institute of the McGill University Health Centre | 2020-10-16 | NCT04869397 |
| 2021-7362 (Control # 246471) |
Fluvoxamine for Early Treatment of COVID-19: A Fully Remote, Randomized Placebo Controlled Trial (STOP COVID 2 Canada) | Fluvoxamine | Research Institute of the McGill University Health Centre | 2020-11-30 | NCT04668950 |
| 2149 (Control # 240138) Authorized under the Clinical Trials Interim Order |
Sedating with Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters and Survival; Multicentre Open-Label, Pragmatic, Randomised Controlled Trial and a Parallel Prospective (Non-Randomised) Cohort Study | Isoflurane, sevoflurane | Sunnybrook Research Institute | 2020-06-10 | NCT04415060 |
| 776228483 PROACTIVE (Control # 240296) |
Propranolol as an Anxiolytic to Reduce the Use of Sedatives for Critically Ill Adults Receiving Mechanical Ventilation: an Open-Label Randomized Controlled Trial. (PROACTIVE) | Propranolol | Ottawa Hospital Research Institute | 2020-06-10 | NCT04467086 |
| AB002 (Control # 238815) |
Multicentre, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Trial of LSALT PEPTIDE as Prevention of Acute Respiratory Distress Syndrome (ARDS) in Patients Infected with SARS-COV-2 (COVID-19) | LSALT Peptide | Arch Biopartners Inc. | 2020-05-07 | NCT04402957 |
| AGN120-3 (Control # 238605) |
A Randomized Open Label Phase 2/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Confirmed COVID-19 Infected Hospitalized Patients. | NP-120 (fenprodil) | Algernon Pharmaceuticals | 2020-04-29 | NCT04382924 |
| AP-RECAP-AKI-03-01 (Control # 243263) |
A Randomized, Double-Blind, Placebo-Controlled, Two-Arm Parallel-Group, Multi-Center Phase 3 Pivotal Trial to Investigate the Efficacy and Safety of Recombinant Human Alkaline Phosphatase for Treatment of Patients with Sepsis Associated Acute Kidney Injury | Recombinant human alkaline phosphatase | AM-PHARM A B.V. | 2020-09-11 | NCT04411472 |
| ARBS CORONA II (Control # 243532) Authorized under the Clinical Trials Interim Order |
Host Response Mediators in Coronavirus (COVID-19) Infection - Is There A Protective Effect of Losartan on Outcomes of Coronavirus Infection? | Losartan | Providence Health Care Saint Paul's Hospital | 2020-09-28 | NCT04606563 |
| ATI0320 (Control # 244962) |
Favipiravir for Post Exposure Prophylaxis in SARS-COV2-exposed Vulnerable Individuals (PEPCO) Double-blinded, Placebo-Controlled, Randomized, Multinational, Phase-3 clinical Trial to Evaluate the Efficacy of Favipiravir in Preventing the Development of COVID-19 When Given to Asymptomatic SARS-CoV2-Negative Individuals Who Had Direct Exposure to a SARS-CoV2 Infected Person. | Favipiravir | Appili Therapeutics Inc. | 2020-11-02 | N/A |
| BAI_COV19_01 (Control # 239071) |
Inhaled NO For The Treatment of COVID-19 Caused by SARS-CoV-2 | Nitric oxide | Beyond Air. Inc. | 2020-05-19 | NCT04456088 |
| BHC-RIB 5401-HC (Control # 238007) |
An Open Label Study to Evaluate the Safety and Efficacy of Virazole® (ribavirin for inhalation solution, USP) in Hospitalized Adult Participants with Respiratory Distress Due to COVID-19 | Virazole® (ribavirin) | Valeant Canada LP/Valeant Canada S.E.C. | 2020-04-08 | NCT04356677 |
| CATCO 2114 (Control # 237108) |
The Canadian arm of the WHO SOLIDARITY Trial. A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients. |
Artesunate/ imatinib/ infliximab/ losartan/ dexamethasone
|
Sunnybrook Research Institute | 2020-03-18 | NCT04330690 |
| CIAO_COVID20 (Control # 246983) |
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial) - An Adaptive Phase II Randomized-Controlled Clinical Trial | Xolair (omalizumab) | The Research Institute of the McGill University Health Centre | 2020-12-21 | N/A |
| CINC424J12301 RUXCOVID (Control # 240395) |
Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy and Safety of Ruxolitinib in Patients with COVID-19 Associated Cytokine Storm (RUXCOVID) | Jakavi (ruxolitinib) | Novartis Pharmaceuticals Canada Inc. | 2020-06-16 | NCT04362137 |
| CIRCA-19 (Control # 238608) |
Cellular Immunotherapy for COVID-19 acute Respiratory Distress Syndrome (ARDS) | Allogeneic Umbilical Cord Mesenchymal Stromal Cells (UC-MSC) | Ottawa Hospital Research Institute | 2020-05-15 | NCT04400032 |
| COLCORONA MHIPS-2020-001 (Control # 237317) |
Colchicine coronavirus SARS-COV2 trial (COLCORONA) | Colchicine | Montreal Heart Institute | 2020-03-20 | NCT04322682 |
| CONCOR-Kids (Control # 238820) |
CONCOR-KIDS: A Randomized, Multicentered, Open-Label Phase 2 Clinical Trial of the Safety and Efficacy of Human Coronavirus-Immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children | Apheresis frozen plasma from recovered COVID-19 patients (convalescent plasma) | C17 Council | 2020-05-04 | NCT04377568 |
| CONTROL-COVID-Favipiravir-1 (Control # 239133) |
Control of COVID-19 Outbreak in Long Term Care | Favipiravir | Appili Therapeutics Inc. | 2020-05-18 | NCT04448119 |
| CORIPREV-1 (Control # 237350) |
COVID-19 Ring-Based Prevention Trial with lopinavir/ritonavir (CORIPREV-LR). | Lopinavir/ Ritonavir | Unity Health Toronto | 2020-03-21 | NCT04321174 |
| COV-01 (Control # 242568) Authorized Under the Clinical Trials Interim Order |
Industry Alliance Platform Trial to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients | Taltz (ixekizumab) / Otezla (apremilast) | Amgen Canada Inc. | 2020-08-20 | NCT04590586 |
| COVACTA (Control #: 237397) |
A Randomised, Double-Blind, Placebo-Controlled, Multicentre Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients with Severe COVID-19 Pneumonia. | Actemra®/RoActemra® (tocilizumab) |
Hoffmann-La Roche Limited | 2020-03-25 | NCT04320615 |
| COVID-CTP-01 (Control # 237786) | Multi-Center, Randomized, Controlled, Phase II Clinical Efficacy Study Evaluating NORS Treatment for the Prevention and Treatment of COVID-19 in Healthcare Workers & Individuals at Risk of Infection | Nitric oxide | Sanotize Research & Development Corp. | 2020-04-18 | NCT04337918 |
| COVID-CTP-02 (Control #240702) | Multi-center, Double-Blinded Placebo-Controlled, Phase II Clinical Efficacy Study Evaluating NORS to Treat and Prevent the Exacerbation of Infection in Individuals with Documented Mild COVID-19 | Nitric oxide | Sanotize Research & Development Corp. | 2020-06-30 | NCT04443868 |
| COVID19 PEP RCT - Canada 2020-6549 (Control #237355) |
Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial (COVID19 PEP RCT - Canada) | Hydroxychloroquine | Research Institute of the McGill University Health Centre | 2020-03-25 | NCT04308668v |
| CTO-3212 (Control # 244591) Authorized under the Clinical Trials Interim Order |
Evaluation of The Potential Benefit of Reninangiotensin System Inhibitors (RASI, ACEI/ARB) in High-Risk Patients with COVID-19 | Cadesartan / valsartan / ramipril / perindopril / irbesartan / losartan / enalapril / captopril | Ottawa Heart Institute Research Corporation | 2020-10-16 | NCT04591210 |
| CTSN-MSC-ARDS001 (Control # 241138) |
Mesenchymal Stromal Cells for the Treatment of Moderate to Severe COVID-19 Acute Respiratory Distress Syndrome | Remestemcel-L | Mesoblast, Inc. | 2020-07-31 | NCT04371393 |
| D1690C00081 (Control # 240352) Authorized under the Clinical Trials Interim Order |
An International, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study Evaluating the Efficacy and Safety of Dapagliflozin in Respiratory Failure in Patients with COVID-19 | Dapagliflozin | Saint Luke's Hospital of Kansas City | 2020-07-04 | NCT04350593 |
| DAL-401 (Control # 246298) Authorized under the Clinical Trial Interim Order |
A Double-Blind, Placebo-Controlled Phase 2A Proof-of-Concept trial of Dalcetrapid in Patients with Confirmed Mild to Moderate COVID-19 | Dalcetrapid | DalCor Pharma UK Ltd | 2020-11-26 | NCT04676867 |
| DISCONNECT-1 (Control # 241689) |
Dismantling COVID Induced Neutrophil ExtraCellular Traps (DISCONNECT-1): Phase I pilot study investigating the safety and feasibility of inhaled rhDNase1 and its impact on neutrophil extracellular traps (NETs) in non-ventilated COVID-19 infected patients | Pulmozyme (dornase alfa) | The Research Institute of the McGill University Health Centre | 2020-07-24 | NCT04409925 |
| EB05-04-2020 (Control # 239462) Authorized under the Clinical Trials Interim Order |
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + Standard of Care (SOC) Vs. Placebo + SOC in Adult Hospitalized Patients with COVID-19 | EB05 | Edesa Biotech Research Incorporated | 2020-06-12 | NCT04401475 |
| EXTENDED-P2 (Control # 240041) |
EXTENDED (Novel Oxygen Therapeutic NaN02 for COVID-19 induced ARDS) Phase IIa Trial | Perflenapent (NaNO2) | Nuvox Pharna LLC |
2020-06-10 | N/A |
| FAST-1 (Control# 244310) Authorized under the Clinical Trials Interim Order |
Nebulized Furosemide For Pulmonary Inflammation in Intubated Patients with COVID-19 - A Phase 2/3 Study | Furosemide | Kingston Health Science Centre | 2020-10-13 | NCT04588792 |
| FIRH_XE006 (Control # 245507) |
Lung Structure-Function in Survivors of Mild and Severe COVID19 Infection : 129XE MRI and CT For Rapid Evaluations and Next Wave Healthcare Planning | Hyperpolarized Xenon-129 | St. Joseph's Healthcare Hamilton | 2020-11-05 | N/A |
| GRAAL-2020-01 (Control # 238201) |
A Randomized, Open-Label Trial of Convalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness (CONCOR-1) | Apheresis frozen plasma from recovered COVID-19 patients (convalescent plasma) | Hamilton Health Sciences | 2020-04-16 | NCT04348656 |
| GS-US-540-5821 (Control # 238163) |
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-COV2 (COV) Infection | Remdesivir | Gilead Sciences Canada Inc. | 2020-04-15 | NCT04323761 |
| HEROS-1 (Control # 237851) |
Protecting Frontline Health Care Workers from COVID-19 with hydroxychloroquine Pre-Exposure Prophylaxis: A randomized, Placebo-controlled Multi-Site Trial in Toronto, Canada | Hydroxychloroquine | University Health Network | 2020-04-03 | NCT04374942 |
| HOPE ABCOV-01 (Control # 237739) |
A randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of oral hydroxychloroquine for the treatment of SARS-CoV-2 positive patients for the prevention of severe COVID-19 disease (Short title: ALBERTA HOPE COVID-19) | Hydroxychloroquine | University of Calgary | 2020-04-09 | NCT04329611 |
| JF-4-2020 (Control # 238558) |
Interferon Lambda for Immediate Antiviral therapy at Diagnosis (ILIAD): A phase II randomized, double-blind, placebo-controlled, multicenter, trial to evaluate the effect of peginterferon lambda for the treatment of COVID-19 | Peginterferon Lambda-1A | University Health Network | 2020-04-29 | NCT04354259 |
JH-COR-003 Authorized under the Clinical Trials Interim Order with Terms and Conditions |
NOVATION-1: A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Safety and Efficacy of Aerosolized Novaferon + SOC vs. Placebo + SOC in Hospitalized Adult Patients with Moderate to Severe COVID-19 | Novaferon (chimeric interferon α) | Genova Inc. | 2020-12-11 | NCT04669015 |
| LAU-20-01 (Control #238614) |
A Double-Blind, Randomized, Placebo-Controlled, Pilot Phase II Study of the Efficacy and Safety of Lau-7B in the Treatment of Adult Hospitalized Patients with COVID-19 Disease | LAU-7B (fenretinide) | Laurent Pharmaceuticals | 2020-05-02 | NCT04417257 |
| 9890 (Control #238851) |
Exogenous Surfactant Administration for Patients with COVID-19 | BLES (bovine lipid extract surfactant suspension) | St. Joseph's Health Centre London | 2020-05-05 | NCT04375735 |
| LOVIT-COVID MP-31-2021-3741 (Control #239705) |
Lessening Organ Dysfunction with VITamin C - COVID (LOVITCOVID) | Vitamin C | Centre de recherche du centre hospitalier universitaire de Sherbrooke | 2020-06-05 | NCT04401150 |
| Mild-CONTAIN 2021-6638 (Control # 239123) |
Mild - CONTAIN CiclesOnide clinical Trial COVID-19 Treatment | Ciclesonide | Research Institute of the McGill University Health Centre | 2020-05-23 | N/A |
| MK-4482-001 (Control # 244315) Authorized under the Clinical Trials Interim Order |
A Phase 2/3 Randomized, Placebo Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety and Pharmacokinetics of MK-4482 in Hospitalized Adults with COVID-19. | MK-4482 | Merck Canada Inc. | 2020-10-19 | NCT04575597 |
| MK-4482-002 (Control # 244159) Authorized under the Clinical Trials Interim Order |
A Phase 2/3 Randomized, Placebo Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults with COVID-19. | MK-4482 | Merck Canada Inc. | 2020-10-19 | NCT04575584 |
| MP-31-2019-2945 (Control # 237164) |
Lessening Organ Dysfunction with Vitamin C (LOVIT) | Vitamin C (ascorbic acid) |
Centre de recherche du centre hospitalier universitaire de Sherbrooke | 2020-03-18 | NCT03680274 |
| MP-37-2021-6659 (Control #238811) |
A Multi-Centre, Randomized, Blinded, Placebo Controlled Clinical Trial of the Safety and Effectiveness of Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Children | Hydroxychloroquine | Research Institute of the McGill University Health Centre | 2020-05-04 | N/A |
| MUHC_CAMOSTAT MESILATE (Control #240313) |
The Impact of the Camostat Mesilate on COVID-19 Infection: A Randomized Controlled Phase II Clinical Trial | Camostat | McGill University Health Centre | 2020-07-02 | N/A |
| NCT04405102 (Control # 241148) |
A Randomized trial on Efficacy and Safety of Ozanimod for the Treatment of COVID-19 Patients Requiring Oxygen Support - a Pilot Trial (COZI) | Ozanimod | Institut universitaire de cardiologie et de pneumologie de Québec | 2020-07-13 | NCT04405102 |
| NTM-CTP-01 (Control # 236728) |
An Open Label Safety Study of Inhaled Gaseous Nitric Oxide (gNO) for Adults & Adolescents with Non-Tuberculous Mycobacteria | Nitric oxide | Dr. Jeremy Road | 2020-03-19 | NCT03331445 |
| OHRI-HBOT-001 (Control # 242108) |
Multicentre Randomized Controlled Trial of Hyperbaric versus Normobaric oxygen therapy for COVID-19 Patients | Oxygen | Ottawa Hospital Research Institute | 2020-07-30 | NCT04500626 |
| ONV2020-003 (Control# 243886) Authorized under the Clinical Trials Interim Order |
A Phase I-Ib, Double-blinded, Randomized Repeated Dose Single Centre, Safety and Immunogenicity Study of Nasal Poly-ICLC (Hiltonol) in Healthy COVID-19 Vaccinated Adults | Hiltonol (Polyriboinosinic acid-polyribocytidylic acid (Poly-ICLC)) | Oncovir, Inc. | 2020-09-25 | NCT04672291 |
| OZM-113 (Control # 238691) | Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC), in collaboration with Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-4) | Innohep (tinzaparin sodium) / Lovenox (enoxaparin sodium) / Fragmin (dalteparin sodium) / heparin sodium | University of Manitoba | 2020-04-29 | NCT04372589 |
| PDC01 (Control #242430) |
A Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety & Efficacy of Dapsone on the Treatment of COVID-19 Positive Patients | Dapsone | Research Institute of the McGill University Health Centre | 2020-08-20 | N/A |
| PHRI.ACT.COVID19 (Control # 238157) |
Anti-Coronavirus Therapies to Prevent Progression of COVID-19 (ACT), a Randomized Trial | Colchicine / acetylsalicylic acid / rivaroxaban | Hamilton Health Sciences | 2020-04-18 | NCT04324463 |
| PREP2020 (Control #238396) |
Pre-Exposure Prophylaxis fro SARS-Coronovirus-2: A Pragmatic Randomized Clinical Trial | Hydroxychloroquine | University of Manitoba | 2020-04-21 | N/A |
| PRO00100606 (Control # 240943) |
Improving Vitamin D Status in the Management of COVID-19 | Vitamin D | Governors of the University of Alberta | 2020-07-27 | NCT04385940 |
| PROTECT (Control # 243196) |
Prevention of COVID-19 with Oral Vitamin D Supplemental Therapy in Essential Healthcare Teams | Cholecalciferol | Centre Hospitalier Universitaire Sainte-Justine | 2020-09-16 | NCT04483635 |
| Protocol 214094 (Control # 239770) |
A Randomized, Double-blind, Placebo-Controlled, Study Evaluating the Efficacy and Safety of Otilimab IV in Patients with Severe Pulmonary COVID-19 Related Disease | GSK3196165 (otilimab) | GlaxoSmithKline | 2020-05-27 | NCT04376684 |
| RAPID COVID COAG (Control #238510) |
Coagulopathy of COVID-19: A pragmatic randomized controlled trial of therapeutic anticoagulation versus standard care as a rapid response to the COVID-19 pandemic (RAPID COVID COAG) | Fondaparinux / Innohep / Fragmin / Lovenox / Lovenox HP / Heparin sodium injection / Heparin sodium and 0.9% sodium chloride injection / Heparin sodium in 5% dextrose injection | Unity Health Toronto | 2020-04-24 | NCT04362085 |
| REB20-0713 (Control # 239287) |
A Prospective, Observational Study to Assess the Efficacy and Safety of Adjunctive Humanized Monoclonal Interleukin 6 Receptor Antibody Tocilizumab (TCZ) Therapy to Standard of Care for the Reduction of Hyperinflammation related Mortality in SARS-Cov2 Positive Patients | Actemra (tocilizumab) | University of Calgary | 2020-05-22 | NCT04423042 |
| REMAP-CAP X17-0199 (Control # 237719) |
Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP): Pandemic appendix to the core protocol |
Heparin sodium/Lovenox/ Fragmin/ Innohep/ vitamin C/ simvastatin/ acetylsalicylic acid/ticagrelor/ clopidogrel/ ramipril/ lisinopril/ perindopril erbumine/ enalapril/ trandolapril, captopril/ losartan potassium/ valsatan, candesartan cilexetil/ irbesartan/ telmisartan/ olmesartan medoxomil | Unity Health Toronto | 2020-04-01 | NCT02735707 |
| ROB0050 (Control # 246389) |
Lung Structure-Function in survivors of mild and severe COVID-19 Infection: 129XE MRI and CT for rapid evaluation and next-wave Healthcare | Hyperpolarized Xenon-129 | Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University | 2020-11-27 | NCT04584671 |
| SAIL-004 (Control # 237708) |
Assessment of Investigational Medications adjunct to Clinical Standard of Care for Treatment of Moderate to Severe Coronavirus Disease (COVID-19) | Baricitinib/tocilizumab | Dr. Lisa Barrett | 2020-04-14 | NCT04321993 |
| SAR153191 (Control # 237332) |
An Adaptive Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients with COVID-19 | Kevzara® (sarilumab) | Sanofi-Aventis Canada Inc. | 2020-03-24 | NCT04315298 |
| U-DEPLOY (OZUHN-001/ Sub-protocol # OZUHN-001-6) (Control # 237848) |
Umbrella Trial Defining Coordinated Approach to Pandemic Trials of COVID-19 and Data Harmonization to Accelerate Discovery | Placenta derived decidual stromal cells (DSC) | University Health Network | 2020-04-07 | NCT04331665 |
| UHNSEMPATICO1 (Control # 244389) |
Semaglutide to reduce Myocardial injury in Patients with COVID-19 | Ozempic (semaglutide) | University Health Network | 2020-10-07 | NCT04615871 |
| VASCEPA-COVID-19 CARDIOLINK-9 (Control # 239025) |
An Investigation on the Effects of Icosapent Ethyl (Vascepa™) on Inflammatory Biomarkers in Individuals with COVID-19 Cardiolink-9 | (Vascepa™) (icosapent) | Canadian Medical and Surgical Knowledge Translation Research | 2020-05-08 | NCT04412018 |
| VIR-7831-5001 (Control # 244708) Authorized under the Clinical Trials Interim Order |
A Phase II/III Randomized, Multi-center, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Monoclonal antibody VIR-7831 for the Early Treatment of Coronavirus Disease 2019 (COVID-19) in Non-Hospitalized Patients | VIR-7831 | Vir Biotechnology, Inc. | 2020-10-13 | NCT04545060 |
CAM-001 (Control # 247212) |
Efficacy of Camostat Mesilate in Reducing Severity of COVID-19 | Camostat/Candesartan | Vancouver General Hospital | 2021-03-22 | N/A |
Page details
- Date modified: